Aradigm Corporation

The US FDA’s most recent set of breakthrough therapy designations went to products that are already in advanced development – including one product that had already sought approval and received a comp

The AMR Action Fund continues to make progress towards making its first investments, but all those efforts will have limited impact on the program of antimicrobial resistance unless reimbursement for

The AMR Action Fund hopes to be operational by the end of 2020 and begin reviewing novel antibiotic candidates to invest in during the first quarter of 2021, interim general manager Martin Bott told t

Two companies – Kiadis Pharma and Aradigm – have formally withdrawn pan-EU marketing authorization applications (MAAs) after they were told these were likely to be rejected. A third company, Actelion,